MANAGEMENT OF THE PATIENT WITH ACUTE LIVER FAILURE
A summary of organ failure complications of ALF is provided in Table 3 .
Coagulopathy
In ALF, overall hemostasis as measured by thromboelastography has been shown to be normal by several compensatory mechanisms, even in patients with markedly elevated INR. 2 In the absence of active bleeding or invasive procedure, it is not advisable to correct the INR with fresh frozen plasma, because clinically significant blood loss is rare and correction obscures trends in the INR, an important marker of prognosis. A platelet count greater than 50 3 10 9/L and fibrinogen greater than 1.5 g/L have been demonstrated to correlate with normal thrombin generation and, indirectly, bleeding. 3 Infection ALF risk for immunoparesis increases susceptibility to infection, which may preclude emergent LT. Therefore, surveillance for infection (including chest radiography and periodic cultures of sputum, urine, and blood) should be undertaken, while maintaining a low threshold for starting antimicrobial therapy. Prophylactic antimicrobials have not been proven to improve 21-day survival in ALF. 4 
Hemodynamics
Patients with ALF typically present a hyperdynamic circulation characterized by high cardiac output and low peripheral vascular resistance, a pattern resembling that of sepsis. For patients who continue to have hypotension despite volume repletion, noradrenaline is the preferred vasopressor, with or without adjunctive use of vasopressin or its analogues. 5 Echocardiography or invasive hemodynamic monitoring (e.g., PiCCO, Swan-Ganz catheter) should be used to assess cardiac function and help titrate decisions on the doses of fluids and/or vasopressors. Relative adrenal insufficiency may be present, and the use of steroids has been associated with a decrease in noradrenaline dose and overall mortality. 
Acute Kidney Injury
Acute kidney injury (AKI) may develop in up to 70% of patients with ALF and has been associated with worse overall survival. 6 Classic indications for renal replacement therapy initiation also apply, including severe acidosis, hyperkalemia, anuria, and/or fluid overload. Further indications may include removal of toxic substances (e.g., ammonia), difficult-to-treat hyponatremia, or difficult-totreat hyperthermia. Continuous renal replacement therapy has been proposed to safer for patients with ALF given the risk for aggravating hypotension and cerebral edema. 7
Cerebral Edema and Intracranial Hypertension
In ALF, astrocyte swelling may result in cytotoxic brain edema, which may culminate in tonsillar herniation and death. Frequent neurological examination (including pupils) and the use of transcranial Doppler are simple strategies to monitor for signs of cerebral edema and intracranial pressure. On the contrary, computed tomographic findings compatible with intracranial hypertension often present too late in the course of this condition. Invasive monitoring of intracranial pressure has not been shown to improve these patients' hospital survival. 8 Nevertheless, it is still not clear whether patients with the highest risk for cerebral edema and intracranial hypertension (e.g., ammonia level > 150 mmol/L, vasopressors requirement, or renal replacement therapy requirement) may benefit from such monitoring capacity. 9 Interventions aimed at prevention of intracranial hypertension include: (1) place head of the bed higher than 30 degrees; (2) use propofol sedation if requiring mechanical ventilation; (3) treat fever (prophylactic hypothermia has not been demonstrated to mitigate intracranial hypertension) 10 ; (4) aim for a mean arterial pressure 75 mm Hg and a cerebral perfusion pressure greater than 50 mm Hg (if using invasive intracranial pressure monitoring); (5) consider using renal replacement therapy; and (6) aim for a serum sodium concentration of 145 to 155 mmol/L with hypertonic saline (3%-30% infusion) for prophylaxis in patients with grade III-IV HE.
Extracorporeal Liver Support Systems
Two extracorporeal liver support systems have been studied in ALF with randomized controlled trials: molecular adsorbent recirculating system (MARS) and highvolume plasmapheresis (HVP). MARS, where blood is dialyzed against a dialysate with albumin, has not been proven to improve 6-month survival in ALF. 11 HVP has been shown to significantly improve hospital survival, especially for patients with contraindications for LT. 12 
LIVER TRANSPLANTATION AND PROGNOSTICATION
LT is the only definitive treatment for patients with ALF. Overall survival after LT has been reported to be lower for patients with ALF in comparison with patients with cirrhosis until 1 year after transplant, but it tends to be similar beyond this period. Cadaveric donor LT has been the norm in ALF, but living-donor transplant has been performed in some large-volume centers with acceptable outcomes. Auxiliary transplantation (partial graft as temporary support for native liver regeneration) has shown reasonable outcomes. Stratifying patients based on their risk for death without LT is crucial to prioritize them for transplantation. King's College criteria have been used worldwide for this purpose (Table 4) . A recent meta-analysis has revealed its prognostic ability in comparison with the Model for End-Stage Liver Disease score: for paracetamol-related ALF, sensitivities were 58% and 80%, respectively, and specificities were 89% and 53%, respectively; for nonparacetamol causes, sensitivities were 58% and 76%, respectively, and specificities were 74% and 73%, respectively. Therefore, King's College criteria remain highly specific for paracetamol-related ALF, but less accurate for nonparacetamol causative factors. More recently, the US Acute Liver Failure Study Group (ALFSG) prognostic index showed good performance characteristics (C-statistic 0.84, specificity 95%) in 1974 patients in the ALFSG registry. 13 This is demonstrated in Table 4 and is a commercially available app.
CONCLUSIONS ALF diagnostic and therapeutic strategies have evolved and are now associated with improved outcomes. New advances in basic and clinical research may potentiate even more such outcomes. Despite this, early patient referral to an LT center, timely intensive care unit therapy, and a comprehensive multidisciplinary strategy in risk stratification and selection for LT will continue to be fundamental steps for a successful approach.
